Tsiodras et al propose testing amantadine to see if any benefits could accrue in combination with neuraminidase inhibitors in pandemic flu.1 The principal attraction seems to be low cost. Although they quote resistance and harms as well as lack of “any demonstrable reduction in transmissibility or pathogenicity,” this does not seem to deter them from their proposal.